[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574980":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":18,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":81,"overallStatus":85,"whyStopped":18,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Integrated care","EXPERIMENTAL","Study visit 1: Participants will first complete a study interview, then will receive a prescription for laboratory testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), gonorrhea, chlamydia, and syphilis. Those who meet eligibility criteria for PrEP will receive a prescription for PrEP (emtricitabine 200 mg (FTC)\u002F25 mg tenofovir alafenamide-emtricitabine (TAF) or once daily emtricitabine 200 mg (FTC)\u002F300 mg tenofovir disoproxil fumarate-emtricitabine (TDF)), and will be referred to the Infectious Diseases clinic for PrEP follow-up. Participants will then complete a standard SUD clinic appointment. Study visit 2: Participants will follow-up at 90 days in the SUD clinic where they will repeat the study interview, followed by receipt of standard SUD clinical care.",[13],"Other: Integrated care",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment as usual","NO_INTERVENTION","Study visit 1: Participants will first complete a study interview, then will complete a standard SUD clinic appointment. After the SUD appointment, participants will be referred to the Infectious Diseases clinic to receive standard infectious diseases laboratory testing, including HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), gonorrhea, chlamydia, and syphilis. Those who meet eligibility criteria for PrEP will receive a prescription for PrEP (emtricitabine 200 mg (FTC)\u002F25 mg tenofovir alafenamide-emtricitabine (TAF) or once daily emtricitabine 200 mg (FTC)\u002F300 mg tenofovir disoproxil fumarate-emtricitabine (TDF) through the infectious diseases clinic. Study visit 2: Participants will follow-up at 90 days in the SUD clinic where they will repeat the study interview, followed by receipt of their standard SUD clinical care.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"OTHER","Receipt of infectious diseases laboratory testing and\u002For PrEP for HIV within a single substance use disorder clinic appointment.",[9],[25],{"name":26,"affiliation":27,"role":28},"Audun J Lier, MD","Northport VA Medical Center, Northport, NY","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","(631) 261-4400","4827","audun.lier@va.gov",[36],{"facility":27,"status":18,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Northport","New York","11768-2200","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-73.34317,40.90093,{"lat":46,"lon":45},[49,51],{"name":26,"role":31,"phone":50,"phoneExt":33,"email":34},"631-261-4400",{"name":26,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":53,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100574980","integrated-care-versus-usual-care-for-opioid-use-disorder-and-infectious-diseases-in-veterans-100574980",false,"NCT06766331","Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder","Inclusion Criteria:\n\n* US Veteran\n* Able to provide written informed consent in English\n* Living in the community (Nassau, Suffolk, Kings, Queens, Bronx, Westchester, Rockland counties, NY)\n* Documented diagnosis of moderate to severe opioid use disorder\n* Seeking care at the Northport VA substance use disorder clinic for opioid use disorder treatment\n* Willing to have HIV, HBV, HCV, or bacterial STI testing to determine negative or positive status\n* Persons who test negative for HIV need to meet CDC PrEP eligibility criteria in the 6 months prior to enrollment\n\nExclusion Criteria:\n\n* Severe medical or psychiatric disability making participation unsafe\n* Unable to provide written consent\n* PrEP exclusion: HIV positive test; HBV positive test",true,"ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"NA","Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.",[72,73,74,75,76,77,78,79,80],"Opioid Use Disorder","HIV","Hepatitis C Virus","Gonorrhea","Chlamydia","Syphilis","Sexually Transmitted Infection","Integrated Care","Medications for Opioid Use Disorder",[82,73,83,84],"Hepatitis C","sexually transmitted diseases","Opioid-Related Disorders","NOT_YET_RECRUITING","2026-04-21",{"date":88,"type":89},"2026-04-24","ACTUAL",{"date":91,"type":66},"2028-04-03",{"date":93,"type":66},"2029-06-29",{"name":5,"class":6},1]